PatientID: HDR89

Okitobba 06, 2023

Color Code

HR: High-Level Resistance
LR: Low-Level Resistance
IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence	
PI	ATV	\mathbf{S}		
	DRV	${f S}$		
	FPV	PLR	;L33F	
	IDV	${f S}$		
	LPV	${f S}$		
	NFV	PLR		
	SQV	${f S}$		
	TPV	PLR		
NRTI	ABC	$_{ m HR}$		
	AZT	$_{ m HR}$		
	D4T	$_{ m HR}$		
	DDI	$_{ m HR}$	D67N;K70R;M184V;K219E;T215IF	
	FTC	$_{ m HR}$		
	LMV	$_{ m HR}$		
	TDF	$_{ m IR}$		
NNRTI	DOR	IR	L100IL;V108IV;K103N	
	EFV	$_{ m HR}$		
	ETR	IR		
	NVP	$_{ m HR}$		
	RPV	$_{ m HR}$		

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS		
PI			
	L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In		
	combination with other PI-resistance mutations, it is associated with reduced susceptibility		
	to LPV, ATV, and DRV.		
	D67N is a non-polymorphic TAM associated with low-level resistance to AZT.		
	K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other		
	TAMs.		
	K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced		
	ABC and TDF susceptibility in combination with other TAMs.		
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate		
	resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to		
NRTI	continued treatment with 3TC or FTC because they increase susceptibility to AZT and		
	TDF and are associated with clinically significant reductions in HIV-1 replication.		
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially		
	low-level resistance to ABC and TDF.		
	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV		
	susceptibility. It is the most commonly transmitted DRM.		

NNRTI	L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it confers high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR and DOR. V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.
INSTI	